Aude Segaliny

Aude Segaliny has a wealth of experience in the scientific field. Aude began their career in 2011 as a PhD Student at INSERM UMR957, University of Nantes, where they studied the biology of interleukin-34 and its role in the pathogenesis of osteosarcoma. In 2015, they moved on to become a Postdoctoral Researcher - Fondation ARC Fellow at UC Irvine, where they leveraged emerging bioengineered technologies, stem cell based therapy, and immunotherapy to address unmet needs for cancer treatment. In 2016, they took on a consulting role at Baylx, Inc., where they advised on the scientific side for the development of animal models for Rheumatoid Arthritis and flow cytometry experiments. Finally, in 2017, Aude began working at Amberstone Biosciences, where they held various roles including Director of Research & Scientific Liaison, Head of Assay Biology & Scientific Liaison, and Group Lead - Assay Biology, and Senior Research Scientist. In these roles, they worked to develop a cutting-edge microfluidic-based single cell platform technology to facilitate high throughput functional screening for immunotherapeutics, with a focus on bispecific antibodies.

Aude Segaliny obtained their Doctor of Philosophy - PhD in Cancer biology & immunology - Molecular and cellular biology from Nantes Universit\u00e9 between 2011 and 2014. Aude also earned a Master degree in Molecular and cellular biology - tumor biology from Universit\u00e9 de Rennes I between 2009 and 2011. Furthermore, they obtained a Master degree in engineering in Agronomy - Animal health and physiology from L'Institut Agro Rennes-Angers between 2008 and 2011.